Moleculin Biotech (MBRX) CEO pay: $339,595 actually paid in FY2024
$MBRX · Moleculin Biotech, Inc.Data through FY2024 — latest proxy filed 2026-03-09, checked for new filings 2026-08-21. Every number links to its source.
0.1× the tracked-company median CEO pay ($3.9M).
Pay vs. Performance (Compensation Actually Paid)
What the CEO was actually paid, by fiscal year
What $100 invested was worth, company vs peer group
Pay-vs-Performance table
| FY | CEO pay on paper | CEO pay actually earned | Other top execs (avg) | Value of $100 invested since FY2021 | Same, peer group since FY2021 | Net income |
|---|---|---|---|---|---|---|
| 2024 | $1.5M | $339,595 | $239,920 | $2.37 | — | -$21.8M |
| 2023 | $1.4M | $1.4M | $705,677 | $17.95 | — | -$29.8M |
| 2022 | $2.0M | $1.5M | $699,277 | $22.16 | — | -$29.0M |
| 2021 | $2.0M | $754,189 | $519,656 | $38.89 | — | -$15.9M |
Frequently asked
How much did the MBRX CEO make in 2024?
$339,595 in Compensation Actually Paid (CAP) as Moleculin Biotech, Inc.'s CEO (the filing reports this year's PEO pay without tagging which named executive it belongs to), updated 2026-03-09.
What is pay vs. performance (PvP)?
An SEC disclosure (Item 402(v), required since FY2022) linking named-executive pay to company total shareholder return (TSR) over up to 5 years.
What is Compensation Actually Paid (CAP)?
CAP starts from the Summary Compensation Table total and adjusts equity awards to fair value as of each year-end/vesting date, rather than grant-date value — see the glossary entry for the full walk-through.
Also on MBRX: SEC & DOJ enforcement actions · CEO track-record ranking · Glossary